ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CRSP CRISPR Therapeutics AG

57.02
1.31 (2.35%)
Last Updated: 19:59:30
Delayed by 15 minutes
Share Name Share Symbol Market Type
CRISPR Therapeutics AG NASDAQ:CRSP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.31 2.35% 57.02 57.03 57.07 58.75 56.39 57.93 1,077,464 19:59:30

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

08/12/2023 9:11pm

Dow Jones News


CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more CRISPR Therapeutics Charts.

By Ben Glickman

 

Shares of Bluebird bio fell after the company's sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor's treatment.

The stock was down 41% to $2.84 on Friday. Shares are down 60% this year.

The company's Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology.

The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug.

Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.

Evercore analysts said in a research note that the announcements gave Casgevy an advantage because of its lack of black-box label and lower price.

 

Write to Ben Glickman at ben.glickman@wsj.com

 

(END) Dow Jones Newswires

December 08, 2023 15:56 ET (20:56 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

1 Year CRISPR Therapeutics Chart

1 Year CRISPR Therapeutics Chart

1 Month CRISPR Therapeutics Chart

1 Month CRISPR Therapeutics Chart